Hepa 1-6
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
The Hepa 1-6 cell line is a valuable tool in cancer research, originating from the BW7756 tumor in C57L mice. These cells are known for their ability to secrete various liver-specific products, including albumin, alpha1-antitrypsin, alpha-fetoprotein, and amylase. Notably, they can thrive in serum-free medium when supplemented with dexamethasone and selenium. 
The Hepa 1-6 tumor model, established in immunocompetent mouse strains like C57L/J and C57BL/6, exhibits a median doubling time of approximately 5-6 days without adverse body weight changes. Importantly, Hepa 1-6 cells demonstrate sensitivity to immunotherapy, responding well to checkpoint blockade antibodies, anti-mPD-1, anti-mPD-L1, and anti-mCTLA-4 treatments. Additionally, their response to radiotherapy is dose-dependent.
Why choose Hepa 1-6 from AcceGen?
The Hepa 1-6 cell line boasts high viability and has been rigorously tested, yielding negative results for ectromelia virus (mousepox) contamination. It maintains sterility, with no presence of bacteria, fungi, or mycoplasma, ensuring reliability in research. Furthermore, its identity has been confirmed through STR analysis, further solidifying its authenticity and utility in scientific investigations.
| Product Code | HEPA 1-6; Hepa-1-6; Hepa1-6 |
| Species | Mouse- C57L |
| Cat.No | ABC-TC077S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Liver |
| Disease | Hepatoma |
| Storage | Liquid Nitrogen |
| Product Type | Mouse Liver Cancer Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
The Hepa 1-6 cell line serves as a murine model for the study of hepatocellular carcinoma (HCC), representing a valuable asset within the realm of cancer research. It is instrumental in the establishment of a tumor model within immunocompetent mice, thereby closely recapitulating clinical conditions and rendering it an optimal platform for the preclinical assessment of immunotherapeutic interventions. This model’s favorable immune profile renders it a robust preclinical immuno-oncology model, thereby expediting the exploration of diverse immunotherapy modalities, either as standalone treatments or in synergistic combinations with radiation therapy, small molecular agents, conventional therapeutics, and emerging compounds.
